AzurRx BioPharma, Inc. (AZRX) financial statements (2021 and earlier)

Company profile

Business Address 1615 SOUTH CONGRESS AVENUE
DELRAY BEACH, FL 33445
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments60112
Cash and cash equivalents60112
Receivables13311
Prepaid expense11100
Total current assets:83523
Noncurrent Assets
Operating lease, right-of-use asset00
Property, plant and equipment00000
Intangible assets, net (including goodwill)55222
Goodwill22222
Intangible assets, net (excluding goodwill)33   
Other undisclosed noncurrent assets00112
Total noncurrent assets:55344
TOTAL ASSETS:139757
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:22211
Accounts payable22211
Accrued liabilities00000
Employee-related liabilities  000
Interest and dividends payable 0 00
Other undisclosed accounts payable and accrued liabilities(0)(0)(1)(0)(0)
Debt12000
Due to related parties 1111
Other liabilities00   
Other undisclosed current liabilities13  00
Total current liabilities:164322
Noncurrent Liabilities
Liabilities, other than long-term debt0    
Other liabilities0    
Other undisclosed noncurrent liabilities   11
Total noncurrent liabilities:0  11
Total liabilities:164344
Stockholders' equity
Stockholders' equity attributable to parent(3)5423
Common stock00000
Additional paid in capital9469533828
Accumulated other comprehensive loss(1)(1)(1)(1)(1)
Accumulated deficit(95)(63)(48)(34)(23)
Stockholders' equity note, subscriptions receivable   (1) 
Total stockholders' equity:(3)5423
TOTAL LIABILITIES AND EQUITY:139757

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
Gross profit:0    
Operating expenses(26)(15)(13)(10)(7)
Other operating expense, net
(Other Expenses)
 (0)   
Other undisclosed operating income (loss)(0) (0)(0)0
Operating loss:(26)(15)(13)(10)(6)
Interest and debt expense(1)(0)(0)(1)(6)
Loss from continuing operations before equity method investments, income taxes:(27)(16)(14)(11)(12)
Other undisclosed loss from continuing operations before income taxes(6)   (2)
Net loss:(33)(16)(14)(11)(15)
Other undisclosed net income attributable to parent 0   
Net loss attributable to parent:(33)(15)(14)(11)(15)
Preferred stock dividends and other adjustments1    
Other undisclosed net loss available to common stockholders, basic(10)    
Net loss available to common stockholders, diluted:(42)(15)(14)(11)(15)

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
Net loss:(33)(16)(14)(11)(15)
Comprehensive loss:(33)(16)(14)(11)(15)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(0)0(0)1(0)
Comprehensive loss, net of tax, attributable to parent:(33)(15)(14)(11)(15)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: